Yale Cancer Center Merges Cutting Edge Research with Personalized Medicine

Video

Related Videos
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Manmeet Singh Ahluwalia, MD
D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
Related Content
Sean McCarthy, DPhil

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024
Article
Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021
Podcast
Yuankai Shi, MD, PhD, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC

April 30th 2024
Article
Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021
Podcast
Heinz-Josef Lenz, MD, FACP, of Keck School of Medicine

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024
Article
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article